来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

已收盘 01-20 16:08:04

13.700

-0.250

-1.79%

最高14.240	最低13.280	成交量222.40万
今开14.000	昨收13.950	日振幅6.88%
总市值61.10亿	流通市值61.10亿	总股本4.46亿
成交额3,049万	换手率0.50%	流通股本4.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":13.7,"timestamp":1768896484004,"preClose":13.95,"halted":0,"volume":2224000,"delay":0,"changeRate":-0.01792114695340502,"floatShares":446000000,"shares":446000000,"eps":-0.711066,"marketStatus":"已收盘","change":-0.25,"latestTime":"01-20 16:08:04","open":14,"high":14.24,"low":13.28,"amount":30490505,"amplitude":0.068817,"askPrice":13.7,"askSize":9500,"bidPrice":13.69,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.59,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768959000000},"marketStatusCode":5,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":13.95,"openAndCloseTimeList":[[1768872600000,1768881600000],[1768885200000,1768896000000]],"volumeRatio":0.694137,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2604918481","title":"每日卖空追踪 | 来凯医药-B 01月19日卖空量成交14.5万股，卖空比例为5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604918481","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604918481?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:30","pubTimestamp":1768811427,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间01月19日，跌3.79%，卖空量成交14.5万股，较上一交易日减少29.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119164034a43c2526&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119164034a43c2526&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2604874184","title":"政策催化叠加价值兑现 国产创新药领域开启景气周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2604874184","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604874184?lang=zh_cn&edition=full","pubTime":"2026-01-19 13:44","pubTimestamp":1768801475,"startTime":"0","endTime":"0","summary":"多款国产新药密集获批、BD交易规模放量、海外临床进展提速，多重积极信号凸显行业高景气度，国产创新药正从研发驱动迈向价值兑现的关键阶段。根据数据统计，2026年开年以来，已有多款国产新药相继获批上市。进入2026年，国内创新药BD授权规模仍持续放量、合作模式升级。近年来，政策支持为行业发展保驾护航，叠加研发实力积累与商业化能力提升，国产创新药正迎来黄金发展时期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119134953a43b8e59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119134953a43b8e59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","BK1574","06887","02105","BK1161","06978","01276"],"gpt_icon":0},{"id":"2603952893","title":"来凯医药-B(02105.HK)午后一度涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603952893","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603952893?lang=zh_cn&edition=full","pubTime":"2026-01-16 13:57","pubTimestamp":1768543026,"startTime":"0","endTime":"0","summary":"每经AI快讯，来凯医药-B(02105.HK)午后一度涨近5%，截至发稿涨3.04%，报13.88港元，成交额1991.83万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163621775579.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163621775579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2603954118","title":"港股异动 | 来凯医药-B(02105)午后涨近5% 美国FDA受理LAE118新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2603954118","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603954118?lang=zh_cn&edition=full","pubTime":"2026-01-16 13:38","pubTimestamp":1768541928,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B(02105)午后涨近5%，截至发稿，涨3.04%，报13.88港元，成交额1991.83万港元。消息面上，来凯医药公布，旗下有望治疗PIK3CA类乳腺癌突变实体瘤的新药LAE118，已获美国药监局(FDA)受理临床试验申请。公司介绍指LAE118是一种新型PI3Kα泛突变选择性抑制剂，为针对PIK3CA突变实体瘤的新型疗法。公告称，公司将与监管机构紧密合作以完成相关申请。凭借其在临床开发和对外授权LAE002(afuresertib)的良好及已验证的实绩，公司致力于为需要新型治疗方案的癌症患者提供这种精准治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2603214675","title":"来凯医药-B01月14日主力净流入436.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603214675","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603214675?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:15","pubTimestamp":1768378523,"startTime":"0","endTime":"0","summary":"01月14日, 来凯医药-B股价涨4.91%，报收14.10元，成交金额6331.7万元，换手率1.01%，振幅7.14%，量比2.61。来凯医药-B今日主力资金净流入436.7万元，上一交易日主力净流出240.9万元。该股近5个交易日上涨1.73%，主力资金累计净流出240.4万元；近20日主力资金累计净流出150.6万元，其中净流出天数为11日。该股主力净额占比0.07%，港股市场排名136/2714。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114161640a4c253db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114161640a4c253db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"1130056406","title":"港股生物医药股集体走高！百奥赛图-B涨超11%，来凯医药-B涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130056406","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130056406?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:43","pubTimestamp":1768354999,"startTime":"0","endTime":"0","summary":"1月14日，港股生物医药股集体走高，$百奥赛图-B(02315)$涨超11%，$来凯医药-B(02105)$、$宜明$昂科(02216)$-B(01541)$涨超5%，$微创$机器人(300024)$-B(02252)$涨超4%，$启明医疗-B(02500)$、$华领医药-B(02552)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c007f4db8ce2cc0ef142359e6d915978","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","02552","02500","02216","02105","02252","BK1191","BK1574","BK1617","BK1100","02315","BK1161","BK1583"],"gpt_icon":0},{"id":"2603521486","title":"港股异动 | 来凯医药-B(02105)涨近7% LAE118新药临床试验申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2603521486","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603521486?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:34","pubTimestamp":1768354491,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B(02105)早盘涨近7%，截至发稿，涨5.88%，报14.23港元，成交额934.24万港元。消息面上，1月14日， 来凯医药宣布，美国食品药品监督管理局（FDA）已经受理LAE118的新药临床试验申请（IND）。LAE118是来凯自主研发的一种新型PI3Kα泛突变选择性抑制剂，用于治疗PIK3CA突变的实体瘤患者。PI3Kα突变在乳腺癌、结直肠癌、肺癌、子宫内膜癌和其它癌症患者中较为常见。目前全球已获批的PI3Kα抑制剂对突变型没有选择性， 因对野生型有很强的活性而耐受性较差，且易产生耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c007f4db8ce2cc0ef142359e6d915978","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2603659483","title":"来凯医药-B(02105)：美国食品药品监督管理局受理LAE118新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2603659483","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603659483?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:14","pubTimestamp":1768349659,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，美国食品药品监督管理局已经受理 LAE118的新药临床试验申请。LAE118是一种新型PI3Kα泛突变选择性抑制剂，用于治疗PIK3CA突变的实体瘤患者。公司将与监管机构紧密合作以完成相关申请。凭借其在临床开发和对外授权 LAE002(afuresertib)的良好及已验证的实绩，公司致力于为需要新型治疗方案的癌症患者提供这种精准治疗。LAE118是一种新型PI3Kα泛突变选择性抑制剂。作为针对PIK3CA突变实体瘤的新型疗法，集团正积极推进此候选药物进入临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B(02105)：美国食品药品监督管理局受理LAE118新药临床试验申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2603659265","title":"每日卖空追踪 | 来凯医药-B 01月13日卖空量成交10.5万股，卖空比例为5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603659265","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603659265?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:30","pubTimestamp":1768293027,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间01月13日，跌1.39%，卖空量成交10.5万股，较上一交易日增加22.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164338a714fca1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164338a714fca1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2603065922","title":"来凯医药-B01月13日主力净流出240.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2603065922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603065922?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:15","pubTimestamp":1768292115,"startTime":"0","endTime":"0","summary":"01月13日, 来凯医药-B股价跌1.39%，报收13.44元，成交金额2794.6万元，换手率0.45%，振幅7.78%，量比1.33。来凯医药-B今日主力资金净流出240.9万元，上一交易日主力净流入313.7万元。该股近5个交易日上涨0.07%，主力资金累计净流出532.6万元；近20日主力资金累计净流出409.3万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113161621a714e033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113161621a714e033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2601627893","title":"每日卖空追踪 | 来凯医药-B 01月08日卖空量成交1.45万股，卖空比例为1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601627893","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601627893?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861028,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间01月08日，跌4.4%，卖空量成交1.45万股，较上一交易日减少86.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164611a4ab4466&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164611a4ab4466&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2601622933","title":"来凯医药-B01月08日主力净流出6.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2601622933","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601622933?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:15","pubTimestamp":1767860134,"startTime":"0","endTime":"0","summary":"01月08日, 来凯医药-B股价跌4.40%，报收13.25元，成交金额1919.8万元，换手率0.32%，振幅4.83%，量比1.12。来凯医药-B今日主力资金净流出6.3万元，上一交易日主力净流入144.6万元。该股近5个交易日下跌2.65%，主力资金累计净流出86.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出775.6万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162020a70221a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162020a70221a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2601135378","title":"每日卖空追踪 | 来凯医药-B 01月06日卖空量成交5.3万股，卖空比例为5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601135378","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601135378?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:30","pubTimestamp":1767688227,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间01月06日，跌3.87%，卖空量成交5.3万股，较上一交易日减少47.52%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163411a4a28919&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163411a4a28919&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2601813374","title":"来凯医药-B01月06日遭主力抛售86.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601813374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601813374?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:15","pubTimestamp":1767687350,"startTime":"0","endTime":"0","summary":"01月06日, 来凯医药-B股价跌3.87%，报收13.40元，成交金额1308.0万元，换手率0.21%，振幅4.38%，量比0.58。来凯医药-B今日主力资金净流出86.2万元，上一交易日主力净流出138.5万元。该股近5个交易日下跌1.11%，主力资金累计净流出126.7万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出614.5万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106162123a4a27a13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106162123a4a27a13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"1127964740","title":"来凯医药（02105）发布2025年12月月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1127964740","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127964740?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:15","pubTimestamp":1767604558,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年1月5日提交的2025年12月股份变动月报显示，公司截至2025年12月31日的注册股本为5,000,000,000股，面值每股0.00001美元，注册股本总额50,000美元，未发生变化。同时，公司于2018年及2023年先后采纳的购股权计划在当月亦无行使、授出或失效数量的变动，相关可行使股份期权数量保持不变；2024年股份奖励计划暂无发股或转让股份记录。本次月报由联席公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"gpt_icon":0},{"id":"2601730882","title":"每日卖空追踪 | 来凯医药-B 01月05日卖空量成交6万股，卖空比例为4.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601730882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601730882?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601826,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间01月05日，涨2.58%，卖空量成交6万股，较上一交易日减少40.59%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163502a49e28d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163502a49e28d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2600066206","title":"每日卖空追踪 | 来凯医药-B 01月02日卖空量成交5.55万股，卖空比例为6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600066206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600066206?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:30","pubTimestamp":1767342628,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间01月02日，涨0.15%，卖空量成交5.55万股，较上一交易日减少74.19%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163322a6eb2a4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163322a6eb2a4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2600701311","title":"每日卖空追踪 | 来凯医药-B 12月31日卖空量成交21.5万股，卖空比例为16.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701311","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600701311?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:30","pubTimestamp":1767169827,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间12月31日，涨2.11%，卖空量成交21.5万股，较上一交易日增加505.63%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163403a48dc722&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163403a48dc722&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2600701343","title":"来凯医药-B12月31日主力净流入80.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701343","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600701343?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:15","pubTimestamp":1767168920,"startTime":"0","endTime":"0","summary":"12月31日, 来凯医药-B股价涨2.11%，报收13.57元，成交金额1761.5万元，换手率0.29%，振幅7.30%，量比0.54。来凯医药-B今日主力资金净流入80.1万元，上一交易日主力净流出74.1万元。该股近5个交易日下跌3.49%，主力资金累计净流出35.5万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出315.2万元，其中净流出天数为11日。该股主力净额占比0.01%，港股市场排名237/2705。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231161634a48db278&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231161634a48db278&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2595461717","title":"来凯医药-B(02105)：LAE103的I期单剂量递增研究完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2595461717","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595461717?lang=zh_cn&edition=full","pubTime":"2025-12-31 08:36","pubTimestamp":1767141407,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，本集团已在澳大利亚启动LAE103的I期单剂量递增研究的受试者入组工作。截至本公告日，首位受试者已完成给药。该SAD研究为一项随机、双盲、安慰剂对照研究，旨在评估LAE103在健康的超重或肥胖症受试者中的安全性、耐受性、药代动力学及药效学特性。本集团目标于2026年第叁季度公布此项SAD研究的顶线数据。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02105"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":-0.0965},{"period":"3month","weight":-0.0099},{"period":"6month","weight":-0.2627},{"period":"1year","weight":0.402},{"period":"ytd","weight":0.028}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.0402},{"period":"1year","weight":0.3564},{"period":"ytd","weight":0.0364}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}